Roche Rocephin otitis media labeling indicates lower efficacy than Augmentin, advantage of parenteral dose.
Executive Summary
ROCHE ROCEPHIN OTITIS MEDIA SINGLE DOSE SHOWS LOWER EFFICACY THAN AUGMENTIN multi-dose regimens and equivalence in efficacy to trimethoprim/sulfamethoxazole, product labeling states. The indication section notes, however, that "the potentially lower clinical cure rate of Rocephin should be balanced against the potential advantages of parenteral therapy." Rocephin (ceftriaxone) was approved Dec. 23 for bacterial otitis media ("The Pink Sheet" Jan. 5, T&G-4).